0371 The Odds Ratio Product: A Novel Tool to Identify Features of Comorbid Insomnia and Sleep Apnea

Umaer Hanif,Alyssa Cairns,Veronica Guadagni,Kari Lambing,Guy Duke,Vincent Mysliwiec
DOI: https://doi.org/10.1093/sleep/zsae067.0371
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Many patients presenting with either OSA or insomnia symptoms exhibit signs of the other condition. This overlap, known as COMISA, is often undetected due to differing diagnostic methods PSG for OSA and clinical symptoms for insomnia. The lack of objective diagnostic criteria for COMISA contributes to its low diagnosis rate. We sought to address this gap by investigating whether the Odds Ratio Product (ORP) algorithm can accurately distinguish between individuals with COMISA, OSA patients, and controls. Methods 2000 patients (50% male/female) were selected from a large clinical cohort, equally grouped into 5 categories of 400 patients: clinic controls (AHI < 5, no insomnia), mild OSA (AHI 5-15), mild OSA and insomnia (defined by presence of self-reported complaints of difficulty initiating sleep, maintaining sleep, experiencing restless sleep, and daytime fatigue), moderate-severe OSA (AHI ≥ 15, ODI ≥ 15), and moderate-severe OSA and insomnia. The OSA and COMISA subgroups were matched by AHI. The ORP was computed using a 3-second sliding window, averaged across each 30-second epoch of PSG total recording time (TRT). Extracted ORP features included mean, minimum, and percent TRT spent in ORP deciles 1-10 (1=deepest sleep; 10=fully awake). Univariate ordinal regression was utilized to classify disease subgroups using each ORP feature as input. Results Each disease subgroup was compared to clinic controls (reference group) and statistically presented in the following rank-ordered format (mild OSA, mild COMISA, moderate-severe OSA, moderate-severe COMISA). Significant discriminatory ORP features for disease subtype were mean ORP in NREM (ORs: 3.51, 9.35, 17.3, 43.8, p < 0.001), minimum ORP (ORs: 5.67, 6.33, 5.62, 12.3, p < 0.001), and percent TRT spent in decile 2 “deep sleep” (ORs: 0.982, 0.969, 0.963, 0.947, p < 0.01) and 7 “transitional sleep” (ORs: 1.05, 1.08, 1.09, 1.11, p < 0.01). Conclusion This study demonstrates the potential utility of the ORP algorithm to identify and discriminate between OSA and COMISA subgroups, the latter being underdiagnosed and inadequately treated in the routine sleep clinic paradigm. These findings suggest that ORP may be a valuable tool in the polysomnographic assessment of comorbid sleep disorders, offering a pathway towards an objective assessment and targeted treatment strategies. Support (if any)
neurosciences,clinical neurology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the effect of quetiapine on sleep, respiration and next - day performance in people with insomnia symptoms, especially those with obstructive sleep apnea (OSA) at the same time. Specifically, through a double - blind, randomized, placebo - controlled crossover study design, the researchers hope to evaluate whether quetiapine, while improving the sleep quality of these patients and reducing respiratory events, will have a negative impact on their cognitive function and driving ability the next day. ### Research Background - **Problem Raised**: Quetiapine is a drug commonly used to treat insomnia symptoms, but its effect and potential side effects on patients with obstructive sleep apnea (OSA) have not been fully studied. - **Research Purpose**: To evaluate the effect of quetiapine on sleep quality, respiratory parameters, and next - day cognitive function and driving performance in OSA patients. ### Methods - **Research Design**: Double - blind, randomized, placebo - controlled crossover study. - **Sample**: 15 OSA patients who reported having difficulty maintaining sleep. - **Intervention Measures**: Participants received 50mg quetiapine or placebo on two different nights respectively, and polysomnography monitoring was carried out before each administration. - **Main Indicators**: Nocturnal sleep parameters (such as AHI, arousal index, sleep efficiency) and next - day cognitive function tests (such as reaction time, driving simulator test). ### Results - **Sleep and Respiratory Parameters**: - Quetiapine significantly reduced AHI (20 ± 12 vs. 27 ± 16 events/hour, p = 0.02). - It reduced the arousal index (25 ± 9 vs. 32 ± 16 times/hour, p = 0.02). - It increased sleep efficiency (87 ± 9% vs. 80 ± 11%, p < 0.01). - It did not worsen nocturnal hypoxemia (mean nocturnal SpO2 94.5 ± 1.5% vs. 94.7 ± 1.2%, p = 0.42). - **Next - Day Performance**: - The next - day alertness in the quetiapine group decreased (median reaction time 382 ± 84 ms vs. 336 ± 48 ms, p = 0.02). - Driving simulator performance was impaired (steering deviation 95 ± 54 vs. 73 ± 39, p = 0.02). ### Conclusions - **Main Findings**: A single - dose low - dose quetiapine can reduce the severity of OSA and improve sleep efficiency, but it may lead to impaired alertness and driving performance the next day. - **Clinical Significance**: Although quetiapine can improve the sleep quality of OSA patients in the short term, its negative impact on next - day function needs further evaluation to determine the safety of long - term use. ### Funding - **Funding Source**: This study was funded by the National Health and Medical Research Investigator (PI Eckert 1196261).